Innovating with purpose

Advancing science.
Inspiring hope.

At Vivacitas Oncology, scientific discovery and patient-focused thinking drive our pursuit of new possibilities for difficult-to-treat cancers.

Patient-centered purposeResearch informed by unmet needs
Science-led developmentInvestigational oncology programs
Collaborative expertiseConnecting research and innovation
About Vivacitas

Rethinking possibilities in cancer research.

Vivacitas Oncology is a private clinical-stage biopharmaceutical company focused on exploring innovative approaches to cancers that remain challenging to treat.

Founded in 2015, the company brings scientific and clinical perspectives together to advance research, evaluate investigational compounds and support the long-term pursuit of meaningful therapeutic progress.

✓ Research focused on difficult-to-treat cancers
✓ Commitment to rigorous scientific evaluation
✓ Collaboration across clinical and scientific disciplines
Read Company Background ↗
Our scientific focus

Research built around the questions that matter.

Our approach examines how drug characteristics, disease biology and clinical evidence may inform future treatment research.

Oncology Innovation

Investigating scientific opportunities in areas with significant unmet medical needs.

Compound Research

Exploring the properties of AR-67, an investigational camptothecin-derived compound.

Clinical Evidence

Reviewing published early-phase research and advancing evidence-informed development decisions.

Research program

Spotlight on AR-67

AR-67 is an investigational, lipophilic camptothecin derivative studied in early clinical research. Earlier publications and company materials describe investigations across multiple tumor types, including recurrent glioblastoma.

INVESTIGATIONAL COMPOUND
AR-67

An oncology research program exploring the potential of a camptothecin analog.

Program Background ↗
Research areaSolid tumorsInvestigated across multiple cancer types
Prior studiesPhase I / IIEarly clinical research referenced in published material
Regulatory historyOrphan Drug DesignationCompany-reported FDA designation for glioblastoma; not marketing approval

Important: AR-67 is investigational. Past study findings do not establish safety or efficacy, and orphan drug designation does not mean FDA approval. This site does not offer patient treatment, prescribing or clinical trial enrollment.

News & scientific reading

Research and company perspectives.

Selected historical company communications and resources. Publication dates are shown where verified; links lead to the source material.

Scientific program

Understanding AR-67 and the research behind it

An introduction to the investigational compound and previously reported development work.

Explore the research →
2022 • Company announcement

Vivacitas presents AR-67 at Biotech Showcase

Explore the archived company announcement about the Biotech Showcase investor conference.

Read announcement →
2022 • Research communication

AR-67 research at a glioblastoma summit

Read an archived update on the company's scientific conference participation.

Read announcement →
Partnership & investment

Progress is built through collaboration.

Explore the company's historical investor information and connect through published contact channels for corporate inquiries.

Investor Information ↗
Connect with us

Start a conversation about science and innovation.

Interested in scientific research, company information or potential collaboration? Use the published company contact channel below.

✉
Company inquiries[email protected]
Contact published in the company's archived announcements; verify that it remains active.
↗
Professional networkVivacitas Oncology on LinkedIn
For medical questions, diagnosis, treatment decisions or emergencies, contact a licensed healthcare professional or local emergency service. Do not send personal health information through this website.

Send a general inquiry

This form opens your email application; no information is stored on this website.

No backend is connected. Your email client must be configured to send the message.